Why is Viridien stock surging today?

Viridian Therapeutics stock has fallen 37.8% year to date, yet the valuation checks still point to the shares looking expensive rather than like a clear bargain.

• The year to date decline of 37.8% raises the question of whether the recent weakness has gone far enough to justify the current share price.

• Future revenue potential from Viridian Therapeutics' pipeline can support higher expectations, but the need to fund ongoing development and potential cash burn may weigh on what investors are willing to pay today.

• With a low value score of 2 out of 6, Viridian Therapeutics does not screen as a clear bargain on the broader valuation checks.

The issue now is whether Viridian Therapeutics' current share price already reflects its prospects, or if the recent share price decline has opened up enough valuation support to interest new investors.

Find out why Viridian Therapeutics' 17.3% return over the last year is lagging behind its peers.

Does Viridian Therapeutics Look Pricey on Sales?

P/S is often the cleaner yardstick for a business like Viridian Therapeutics, where earnings are not yet a steady anchor. On this metric, Viridian Therapeutics trades on a P/S of 29.7x, which is well above the Biotechs industry average of 11.2x and also above the peer group average of 17.5x.

The tailored Fair Ratio, which adjusts for factors such as growth prospects, margins, size and risk, sits at just 0.1x. The gap between this and the current 29.7x suggests the model is heavily penalising Viridian Therapeutics for its losses and risk profile. As a result, the figure is better read as a warning flag than a precise target level. Even so, the direction of the signal is clear; the stock screens as richly priced on revenue compared with sector norms.

On the P/S multiple, Viridian Therapeutics stock appears expensive relative to both industry benchmarks and the modelled fair range.

See what the numbers say about this price — find out in our valuation breakdown.

The Viridian Therapeutics Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Viridian Therapeutics pick up where the valuation puzzle leaves off by spelling out which combinations of future growth, margins and earnings would need to hold for Viridian Therapeutics' stock to be worth materially more, or less, than today's price. Rather than relying on a single multiple or model, each Narrative lays out the assumptions behind its view of fair value so you can compare them with the company's actual results over time on the Community page.